Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Merola

Showing results (311-320 of 351) with videos related to

Pageof 36
Sort By:
The Journal of Investigative Dermatology|June 1, 2025
Eosinophilic Fasciitis and Morphea Share Gene Signatures of Inflammatory Cell Death, Self-DNA Recognition, and Enhanced Jak/Signal Transducer and Activator of Transcription SignalingWilliam J Crisler, Rachael Rowley, Oluwadamilola Oke, et al.
JAMA Dermatology|January 24, 2024
Patient-Reported Outcome Measures for Health-Related Quality of Life in Patients With Psoriasis: A Systematic ReviewLourdes M Pérez-Chada, Zachary H Hopkins, Deepak M W Balak, et al.
Rheumatology (Oxford, England)|March 16, 2026
Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studiesLaure Gossec, Laura C Coates, Robert B M Landewé, et al.
JAMA Dermatology|July 9, 2025
Ixekizumab and Malignant Neoplasms: A Pooled Analysis of Data From 25 Randomized Clinical TrialsJoseph F Merola, Kim A Papp, Atul Deodhar, et al.
Rheumatology (Oxford, England)|September 1, 2020
Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritisLaura C Coates, Joseph F Merola, Philip J Mease, et al.
The British Journal of Dermatology|August 10, 2023
Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD studyJoseph F Merola, Albert S Chiou, Emmanuel During, et al.
Annals of the Rheumatic Diseases|September 11, 2023
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL studyChristopher T Ritchlin, Laura C Coates, Iain B McInnes, et al.
JAMA Dermatology|April 29, 2026
The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A ReviewSamip Sheth, Joseph F Merola, Brittany N Weber, et al.
Nature Reviews. Rheumatology|January 26, 2026
Recommendations for the use of CLASI as an outcome measure in cutaneous lupus erythematosus clinical trialsGrace Lu, Tyler Cepica, Catherine Barbey, et al.
The British Journal of Dermatology|May 4, 2019
Developing classification criteria for skin-predominant dermatomyositis: the Delphi processJ S S Concha, S Pena, R G Gaffney, et al.
Pageof 36

Showing results (311-320 of 351) with videos related to

Sort By:
Pageof 36
The Journal of Investigative Dermatology|June 1, 2025
Eosinophilic Fasciitis and Morphea Share Gene Signatures of Inflammatory Cell Death, Self-DNA Recognition, and Enhanced Jak/Signal Transducer and Activator of Transcription SignalingWilliam J Crisler, Rachael Rowley, Oluwadamilola Oke, et al.
JAMA Dermatology|January 24, 2024
Patient-Reported Outcome Measures for Health-Related Quality of Life in Patients With Psoriasis: A Systematic ReviewLourdes M Pérez-Chada, Zachary H Hopkins, Deepak M W Balak, et al.
Rheumatology (Oxford, England)|March 16, 2026
Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studiesLaure Gossec, Laura C Coates, Robert B M Landewé, et al.
JAMA Dermatology|July 9, 2025
Ixekizumab and Malignant Neoplasms: A Pooled Analysis of Data From 25 Randomized Clinical TrialsJoseph F Merola, Kim A Papp, Atul Deodhar, et al.
Rheumatology (Oxford, England)|September 1, 2020
Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritisLaura C Coates, Joseph F Merola, Philip J Mease, et al.
The British Journal of Dermatology|August 10, 2023
Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD studyJoseph F Merola, Albert S Chiou, Emmanuel During, et al.
Annals of the Rheumatic Diseases|September 11, 2023
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL studyChristopher T Ritchlin, Laura C Coates, Iain B McInnes, et al.
JAMA Dermatology|April 29, 2026
The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A ReviewSamip Sheth, Joseph F Merola, Brittany N Weber, et al.
Nature Reviews. Rheumatology|January 26, 2026
Recommendations for the use of CLASI as an outcome measure in cutaneous lupus erythematosus clinical trialsGrace Lu, Tyler Cepica, Catherine Barbey, et al.
The British Journal of Dermatology|May 4, 2019
Developing classification criteria for skin-predominant dermatomyositis: the Delphi processJ S S Concha, S Pena, R G Gaffney, et al.
Pageof 36